CHX Technologies is a research-intensive pharmaceutical company with a unique focus on preventive oral healthcare. CHX has an approved drug, Prevora, which manages the primary cause of poor oral health in adults — a condition called oral dysbiosis. Prevora is a high-strength, sustained-release, broad spectrum antiseptic applied by a hygienist or nurse to the teeth of high risk adults experiencing cavities and/or oral inflammation. Prevora is painless, very safe, very effective and its application is quick. Prevora patients enjoy years of improved oral health and commonly report they feel better too. CHX has approval for Prevora in Canada, Ireland, the UK and the EU. CHX is conducting studies to integrate Prevora in to medical practices, hospitals, seniors’ centres and pharmacies so as to expand access to oral healthcare.

CHX is a private Canadian pharmaceutical company focused on preventive oral healthcare to enable Healthy Aging.

We have developed a first-in-class treatment, Prevora, which manages the bacteria  causing poor oral health (both dental decay and gum disease). Prevora is designed for Healthy Aging. Indeed, that’s how Healthy Agers see it too.

Prevora is a quick, painless & affordable procedure which can be conducted where Healthy Agers live and spend their time. Prevora saves money and inconvenience and has been rated by Canadian seniors as “very important” and “with a very positive effect on my general health.”

Poor oral health, next to hypertension, is the most common chronic disease. It is also the most expensive to treat and has a significant impact on other chronic disorders (diagram), and in turn on medical visits and hospitalization.

CHX is motivated by the size of the problem called poor oral health, the simplicity of its solution with Prevora, and the many opportunities for the delivery of this unique preventive care which can help so many.

The roots of CHX are at the University of Toronto where researchers originated the concept of treating the bacteria causing dental decay with a strong, sustained-release antiseptic.

CHX commercialized this discovery with years of pre-clinical and clinical studies, manufacturing studies and regulatory approvals for Prevora to become the first preventive treatment for dental decay in high-risk adults.

Over the past 10 years, Canadian dental professionals have used Prevora to prevent cavities and to treat gum disease proving how cost-effective and compelling Prevora is to older, high-risk adults.

Most recently, Prevora has been spurred by the social movement to Healthy Aging and by Prevora’s ability to integrate preventive dental care into community settings such as a seniors’ centre, a hospital, a medical practice and long-term care facilities.